Aquestive Therapeutics Inc (AQST) News

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

Sherry Korczynski joins the leadership team as Senior Vice President, Sales and MarketingDr. Stephen Wargacki...

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024...

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure...